Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorWilson, Brooke
dc.contributor.authorArmstrong, Andrew J.
dc.contributor.authorde Bono, Johann S
dc.contributor.authorSternberg, C. N.
dc.contributor.authorRyan, Charles
dc.contributor.authorScher, Howard I.
dc.contributor.authorCarles Galceran, Joan
dc.date.accessioned2022-09-06T11:34:05Z
dc.date.available2022-09-06T11:34:05Z
dc.date.issued2022-07
dc.identifier.citationWilson BE, Armstrong AJ, de Bono J, Sternberg CN, Ryan CJ, Scher HI, et al. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. Eur J Cancer. 2022 Jul;170:296–304.
dc.identifier.issn0959-8049
dc.identifier.urihttp://hdl.handle.net/11351/8034
dc.descriptionAbiraterone acetate; Metastatic castration-resistant prostate cancer; Metformin
dc.description.abstractBackground The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. Objective To determine whether metformin or statins ± abiraterone acetate plus prednisone/prednisolone (AAP) influence OS and PSA-RR. Design, setting and participant COU-AA-301 and COU-AA-302 patients were stratified by metformin and statin use. Cox proportional hazards models were used to estimate hazards ratio (HR) stratified by concomitant medications, and a random effects model was used to pool HR. We compared PSA-RR using Chi χ2 test. Results In COU-AA-301-AAP, metformin was associated with improved PSA-RR (41.1% versus 28.6%) but not prolonged OS. In COU-AA-301-placebo-P, there was no association between metformin and prolonged OS or PSA-RR. In COU-AA-302-AAP, metformin was associated with prolonged OS (adjHR 0.69, 95% CI 0.48–0.98) and improved PSA-RR (72.7% versus 60.0%). In COU-AA-302-P, metformin was associated with prolonged OS (adjHR 0.66, 95% CI 0.47–0.93). In pooled analysis, OS was prolonged among those treated with metformin (pooled HR 0.77, 95% CI 0.62–0.95).In COU-AA-301-AAP, statins were associated with an improved OS (adjHR 0.76, 95% CI 0.62–0.93), while there was no difference in COU-AA-301-P. There was no association with statins and OS in either COU-AA-302 groups. When pooling HR, OS was prolonged among those treated with statins (pooled HR 0.78, 95% CI 0.68–0.88). Conclusion Within the limitations of post-hoc sub-analyses, metformin and statins are associated with a prolonged OS and increased PSA-RR, particularly in combination with AAP.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesEuropean Journal of Cancer;170
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPròstata - Càncer - Tractament
dc.subjectMetàstasi
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshProstatic Neoplasms, Castration-Resistant
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshTreatment Outcome
dc.titleEffects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ejca.2022.03.042
dc.subject.decsneoplasias prostáticas resistentes a la castración
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1016/j.ejca.2022.03.042
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Wilson BE] Princess Margaret Cancer Centre, Toronto, Canada. Faculty of Medicine, University of New South Wales, Kensington, Australia. Kinghorn Cancer Centre, St Vincents Hospital, Darlinghurst, Sydney, Australia. [Armstrong AJ] Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham NC, USA. [de Bono J] The Institute of Cancer Research and Royal Marsden Hospital, London, UK. [Sternberg CN] Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York, NY 10021, USA. [Ryan CJ] Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA. [Scher HI] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. [Carles J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid35568679
dc.identifier.wos000833527200006
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record